Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2017

01-04-2017 | Gastrointestinal Oncology

How Do We Bridge the West and the East in the Treatment for Gastric Cancer?

Authors: Koichi Suda, MD, PhD, FACS, Yuko Kitagawa, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 4/2017

Login to get access

Excerpt

In 2012, gastric cancer (GC) was the fifth most common malignancy and the third leading cause of cancer death in the world.1 The prevalence of GC remains more common in countries of the Far East, including Japan and Korea, than in countries of the West.2 Moreover, better overall survival (OS) has been reported in Eastern trials than the Western series (East vs West 5-year OS: 60–70 vs 30–40 %)3‐7 Eastern investigators may argue that this difference is attributable to more radical surgery, whereas Western investigators may claim that this difference is attributable to earlier detection and differences in biology.8,9 …
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMed
3.
Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMed
4.
Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMed
5.
Nashimoto A, Nakajima T, Furukawa H, et al. Randomized trial of adjuvant chemotherapy with mitomycin, fluorouracil, and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21:2282–7.CrossRefPubMed
6.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRefPubMed
7.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefPubMed
8.
Markar SR, Karthikesalingam A, Jackson D, Hanna GB. Long-term survival after gastrectomy for cancer in randomized, controlled oncological trials: comparison between West and East. Ann Surg Oncol. 2013;20:2328–38.CrossRefPubMed
9.
Yamamoto M, Rashid OM, Wong J. Surgical management of gastric cancer: the East vs. West perspective. J Gastrointest Oncol. 2015;6:79–88.PubMed
10.
Ikoma N, Blum M, Chiang YJ, et al. Race is a risk for lymph node metastasis in patients with gastric cancer. Annals of Surgical Oncology. New York; Springer; 2016, vol 23, p. S177
11.
12.
13.
Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet. 1997;349:1725–9.CrossRefPubMed
14.
Willis J, Riddell RH. Biology versus terminology: East meets West in surgical pathology. Gastrointest Endosc. 2003;57:369–76.CrossRefPubMed
15.
Lauwers GY, Shimizu M, Correa P, et al. Evaluation of gastric biopsies for neoplasia: differences between Japanese and Western pathologists. Am J Surg Pathol. 1999;23:511–8.CrossRefPubMed
16.
Van Cutsem E, Dicato M, Geva R, et al. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol. 2011;22(Suppl 5):v1–9.CrossRefPubMed
17.
18.
Kaise M, Kato M, Tajiri H. High-definition endoscopy and magnifying endoscopy combined with narrow band imaging in gastric cancer. Gastroenterol Clin North Am. 2010;39:771–84.CrossRefPubMed
19.
Gotoda T, Ho KY, Soetikno R, Kaltenbach T, Draganov P. Gastric ESD: current status and future directions of devices and training. Gastrointest Endosc Clin North Am. 2014;24:213–33.CrossRef
Metadata
Title
How Do We Bridge the West and the East in the Treatment for Gastric Cancer?
Authors
Koichi Suda, MD, PhD, FACS
Yuko Kitagawa, MD, PhD, FACS
Publication date
01-04-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5647-8

Other articles of this Issue 4/2017

Annals of Surgical Oncology 4/2017 Go to the issue

Gastrointestinal Oncology

Prognostic Significance of Basing Treatment Strategy on the Results of Photodynamic Diagnosis in Advanced Gastric Cancer

Original Article – Gastrointestinal Oncology

An Isoperistaltic Jejunum-Later-Cut Overlap Method for Esophagojejunostomy Anastomosis After Totally Laparoscopic Total Gastrectomy: A Safe and Feasible Technique

Gastrointestinal Oncology

Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer

Gastrointestinal Oncology

Preclinical Evaluation of Cathepsin-Based Fluorescent Imaging System for Cytoreductive Surgery

Gastrointestinal Oncology

Harvest of at Least 23 Lymph Nodes is Indispensable for Stage N3 Gastric Cancer Patients

Gastrointestinal Oncology

Prognostic Factors for Locoregional Recurrence in Patients with Thoracic Esophageal Squamous Cell Carcinoma Treated with Radical Two-Field Lymph Node Dissection: Results from Long-Term Follow-Up